ArticleChemMedChem2008
Molecular recognition of small-cell lung cancer cells using aptamers.
Article in ChemMedChem, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed.
- Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for rapid detection of the lung cancer biomarker USE1.Journal of nanobiotechnology · 2026Article
- L-Histidine Modulates the Catalytic Activity and Conformational Changes of the HD3 Deoxyribozyme.Genes · 2024Article
- The Application of Aptamer and Research Progress in Liver Disease.Molecular biotechnology · 2024Review
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
- Aptasensors versus immunosensors-Which will prevail?Engineering in life sciences · 2022Review
- A review on corona virus disease 2019 (COVID-19): current progress, clinical features and bioanalytical diagnostic methods.Mikrochimica acta · 2022Review
- Pheno-SELEX: Engineering Anti-Metastatic Aptamers through Targeting the Invasive Phenotype Using Systemic Evolution of Ligands by Exponential Enrichment.Bioengineering (Basel, Switzerland) · 2021Article
- Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors.International journal of molecular sciences · 2021Review
- Aptamers and antibodies: rivals or allies in cancer targeted therapy?Exploration of targeted anti-tumor therapy · 2021Review
- Metal-Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications.Nano-micro letters · 2020Review
- Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer.iScience · 2020Article
- Quantitative detection of neurotransmitter using aptamer: From diagnosis to therapeutics.Journal of biosciences · 2020Review
- In Vitro Selection of a DNA Aptamer by Cell-SELEX as a Molecular Probe for Cervical Cancer Recognition and Imaging.Journal of molecular evolution · 2019Article
- DNA-supramolecule conjugates in theranostics.Theranostics · 2019Review
- An automated microfluidic system for selection of aptamer probes against ovarian cancer tissues.Biomicrofluidics · 2019Article
- [Screening of nucleic acid aptamer of lung cancer cells based on cell exponential enrichment ligand system evolution and its application in tumor diagnosis and treatment].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2018Review
- TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Aptamer-based targeted therapy.Advanced drug delivery reviews · 2018Review
- Aptamers: novelty tools for cancer biology.Oncotarget · 2018Review
- Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Early diagnosis is the way to improve the rate of lung cancer survival, but is almost impossible today due to the lack of molecular probes that recognize lung cancer cells sensitively and selectively. We developed a new aptamer approach for the recognition of specific small-cell lung cancer (SCLC) cell-surface molecular markers. Our approach relies on cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX) to evolve aptamers for whole live cells that express a variety of surface markers representing molecular differences among cancer cells. When applied to different lung cancer cells including those from patient samples, these aptamers bind to SCLC cells with high affinity and specificity in various assay formats. When conjugated with magnetic and fluorescent nanoparticles, the aptamer nanoconjugates could effectively extract SCLC cells from mixed cell media for isolation, enrichment, and sensitive detection. These studies demonstrate the potential of the aptamer approach for early lung cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.